Data for: Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis
https://doi.org/10.48360/jcps-gw67
The concentration of 1463 proteins were measured using the Olink Explore platform which uses Proximity Extension Assay (PEA) technology. The proteins are preselected from four Olink panels: Explore 384 Cardiometabolic, Explore 384 Inflammation, Explore 384 Neurology, and Explore 384 Oncology. The protein concentrations are given as Olink’s relative protein quantification unit on log2 scale: Normalized Protein Expression (NPX). The NPX values were intensity normalized by Olink. Protein levels were measured in cerebrospinal fluid samples (n = 186) and plasma samples (n = 165) from persons with multiple sclerosis and healthy controls.
The dataset was originally published in DiVA and moved to SND in 2024.
Documentation files
Documentation files
Citation and access
Citation and access
Data access level:
Creator/Principal investigator(s):
- Mika Gustafsson - Linköping University - Department of Physics, Chemistry and Biology
Research principal:
Data contains personal data:
Yes
Type of personal data:
The data is pseudonymised and contains information if samples are from persons with MS or healthy controls, and the age and sex of these persons.
Code key exists:
Yes
Sensitive personal data:
Yes
Citation:
Language:
Method and outcome
Method and outcome
Population:
Cerebrospinal fluid (CSF) samples and plasma samples were taken from 92 persons with CIS or RRMS at Linköping University Hospital, Sweden and 51 persons with CIS or RRMS at the Karolinska University Hospital, Sweden. Everyone fulfilled the revised McDonald criteria from 2010 and 2017 for CIS or Multiple sclerosis (MS). Age-matched healthy controls (HC) were recruited from healthy blood donors (23 at the Linköping University hospital and 20 at the Karolinska University Hospital).
Time method:
Study design:
- Observational study
- Case-control study
Data format/data structure:
Administrative information
Administrative information
Other research principals:
Ethical Review
Ethical Review
Reviewer:
- Linköping Ethical Review Board
Registration number:
2017/288-31
Reviewer:
- Linköping Ethical Review Board
Registration number:
2016/305-32
Reviewer:
- Stockholm Ethical Review Board
Registration number:
2022-03650-02
Reviewer:
- Linköping Ethical Review Board
Registration number:
2013/155-32
Reviewer:
- Linköping Ethical Review Board
Registration number:
2016/304-32
Reviewer:
- Linköping Ethical Review Board
Registration number:
2014/311-31
Funding
Funding
Funding agency:
- European Union's Marie Sklodowska-Curie
Funding agency:
- Swedish Brain Foundation
Funding agency:
- Swedish Foundation for Strategic Research
Funding agency:
- Knut and Alice Wallenberg Foundation
Funding agency:
- Margareth AF Ugglas Foundation
Funding agency:
- Swedish Research Council
Funding agency:
- Swedish Knowledge Foundation
Funding agency:
- Medical Research Council of Southeast Sweden
Funding agency:
- NEURO Sweden
Funding agency:
- ALF grants
Funding agency:
- Östergötland Region
Funding agency:
- Swedish Foundation for MS Research
Topic and keywords
Topic and keywords
CESSDA topic classification:
Swedish Standard Classification of Research Subjects 2025:
Keywords:
Relations
Relations
Publications
Publications
Citation:
Åkesson, J., Hojjati, S., Hellberg, S., Raffetseder, J., Khademi, M., Rynkowski, R., … Gustafsson, M. (2023). Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-42682-9
